Cognivue®

Charles J. Duffy, MD, PhD

Founder and CEO

May 10, 2017

Cognivue is an artificial intelligence neurological tool,

not a computerized psychological questionnaire

COGNIVUE ENABLES CARE

2

Cognivue promotes cost-effective dementia care

in primary care office practices

Cognivue aligns patients, families, and practitioners by

moving beyond dementia as an accusation

3

LocalMotion

GlobalPattern

LocalMotion

GlobalPattern

LocalMotion

GlobalPattern

Psychophysics Distinguishes Aging and AD

Mo

tio

n C

oh

eren

ce T

hre

sho

ld

ORIGINS OF COGNIVUE

4

UTILITY OF COGNIVUE

Year in Study (off treatment)

0

10

20

30

40

50

60

70

1 2

ON Radial IO

ON Radial Out

ON Planar

AD Radial IO

AD Radial Out

AD Planar

NAD = 12

NON = 31

One Year Longitudinal Study in Aging and AD M

oti

on

Co

heren

ce T

hresh

old

One Year Longitudinal Study in Aging and AD

Stability in normal aging

Decline in early Alzheimer’s

Detect and monitor disease neurological deficits

Monitor

Detect

5

NEURAL MECHANISMS OF COGNIVUE

6

LINKS TO AGING AND ALZHEIMER’S

Hyperactivity of soluble AβLoss od activity with Aβ plaques

Loss of signal coherencein aging and early AD

SIX KEY POINTS

7

1. Detect functional impairment

2. Monitor disease progression

3. Assess therapeutic efficacy

4. Access neural mechanisms

5. Foundation of complex behaviors

6. Domain-specific impairment measures

Shape Processing

Occipital

Language

Parietal

Temporal

Language Processing

cat

dal

daf

cbt

gca

erfltv

kif

ris

pfg

Visuo-Motor Function

Motion Processing

Dynamic Adaptation

Spatial Attention

Temporal Integration

Learning & Memory

Bottom-Up Processing

8

COGNIVUE COMMERCIALIZATION

9

COGNIVUE PSYCHOPHYSICAL TESTING

Motor

Control Report Generation

Visual

Salience

Sensory-Motor Testing

Calibrate

to Patient

Perceptual Testing Shapes

Motion

Letters

Words

Calibrate

to Patient

Memory Testing Shapes

Motion

Letters

Words

Calibrate

to Patient

Cloud Archives

Post-hocAnalyses

Contextualized

F/U Testing

Practitioners& Researchers

Doe, John02-01-1956

Secure access on Cognivue, desktops, and portable devices

10

THE COGNIVUE SYSTEM

N = 356 subjects tested twice

Cognivue re-test correlation = .90

PPA = .89, NPA = .93, ICC = .94

SLUMs re-test correlation = .82

PPA = .87, NPA = .87, ICC = .87

11

COGNIVUE’S FDA VALIDATION

N = 401 subjects 55- 95 yo

impaired vs. unimpaired

Cognivue vs. SLUMS

PPA & NPA

.82 & .98

1) Objective psychophysics

2) Neurological assessment

3) Linked to brain electrical activity

4) 10 minute testing in doctor’s office

5) Simple test interpretation algorithm

6) Easily explained to patients and families

12

COGNIVUE’S ADVANTAGES

Cognitive Disorders – Dementias, Deliriums, Syndromes

Movement Disorders – Parkinsonism and overlap syndromes

Affective Disorders – Depressions, Manias, Psychoses

Acquired Disorders – Head injury and medicinal SEs

Developmental Disorders – Conditions and Pathopotential

PLATFORM TECHNOLOGY TARGETS

13

14

COGNIVUE CONTINUING EXPANSION

Domain-specific cortical function

Bringing cognitive care to primary care

15